Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

HALOZYME THERAPEUTICS, INC. (HALO) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

HALOZYME THERAPEUTICS, INC. (HALO), most recent 12 months reported: revenue $1.66B, net income $413.6M, free cash flow $806.22M. Latest balance sheet on file: liquid cash $231M, total debt $2.15B, net cash -$1.92B. From SEC filings. Others in Biological Products, (No Diagnostic Substances): NEUROCRINE BIOSCIENCES INC · Exelixis Inc · Moderna, Inc. · QIAGEN N.V. · BIO-TECHNE Corp · BIOCRYST PHARMACEUTICALS, INC. · REPLIGEN CORP · TARSUS PHARMACEUTICALS, INC.

Stock screener

Watchlist